--Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha to its Precise™ Oncology Solutions portfolio. "FRα, alongside ...

Treatment with Elahere (mirvetuximab soravtansine-gynx) showed consistent survival benefits in a long-term analysis from the phase 3 trial MIRASOL evaluating patients with folate receptor ...

Source Reference: Matulonis UA, et al "Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from ...

"More that 90% of ovarian cancer overexpresses folate receptor alpha," he noted. Coleman presented the findings at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer.

AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer ...

FR-alpha helps get folate, a B vitamin, into cells. There’s evidence that aggressive ovarian cancer cells have a lot more of these receptors than normal tissue.

Elahere, known in development as mirvetuximab soravtansine, targets folate receptor alpha, a protein abundant on the surface of ovarian cancer cells. The drug is approved for treating patients ...